Literature DB >> 32814817

Identification of the hypertension drug niflumic acid as a glycine receptor inhibitor.

Daishi Ito1, Yoshinori Kawazoe2, Ayato Sato3, Motonari Uesugi4, Hiromi Hirata5.   

Abstract

Glycine is one of the major neurotransmitters in the brainstem and the spinal cord. Glycine binds to and activates glycine receptors (GlyRs), increasing Cl- conductance at postsynaptic sites. This glycinergic synaptic transmission contributes to the generation of respiratory rhythm and motor patterns. Strychnine inhibits GlyR by binding to glycine-binding site, while picrotoxin blocks GlyR by binding to the channel pore. We have previously reported that bath application of strychnine to zebrafish embryos causes bilateral muscle contractions in response to tactile stimulation. To explore the drug-mediated inhibition of GlyRs, we screened a chemical library of ~ 1,000 approved drugs and pharmacologically active molecules by observing touch-evoked response of zebrafish embryos in the presence of drugs. We found that exposure of zebrafish embryos to nifedipine (an inhibitor of voltage-gated calcium channel) or niflumic acid (an inhibitor of cyclooxygenase 2) caused bilateral muscle contractions just like strychnine-treated embryos showed. We then assayed strychnine, picrotoxin, nifedipine, and niflumic acid for concentration-dependent inhibition of glycine-mediated currents of GlyRs in oocytes and calculated IC50s. The results indicate that all of them concentration-dependently inhibit GlyR in the order of strychnine > picrotoxin > nifedipine > niflumic acid.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32814817      PMCID: PMC7438329          DOI: 10.1038/s41598-020-70983-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Glycine, one of the major neurotransmitters, binds to glycine receptor (GlyR), mediating fast inhibitory synaptic transmission in the brain stem and the spinal cord[1,2]. Inhibitory glycinergic transmission is involved in generating rhythms such as respiration and walking/running. GlyRs are pentameric ligand-gated chloride-permeable channels. Extensive studies of mammalian GlyRs have identified four α subunit genes (GLRA1, GLRA2, GLRA3 and GLRA4) and a single β subunit gene (GLRB) with the GLRA4 being a pseudogene in human[3-8]. Since mutations in a gene encoding α1 or β subunit of GlyR causes startle reflex defects, which are often referred to as hyperekplexia in human, the major GlyRs in mammals is composed of α1 and β subunits[9,10]. GlyRs have also been studied in zebrafish, a vertebrate model, that offer several advantages such as production of many offspring, fast development, optical transparency during embryogenesis and ease of pharmacological assay. Zebrafish have five α subunit (glra1, glra2, glra3, glra4a and glra4b) and two β subunit (glrba and glrbb) genes[11]. The existence of two paralogs of a mammalian gene is not uncommon in zebrafish due to an ancestral gene duplication during fish evolution[12]. Both glra1 mutant and glrbb mutant zebrafish showed touch-evoked simultaneous contractions of bilateral muscles, and as a consequence startle reflex just like strychnine-treated zebrafish embryos exhibited[13,14]. Thus, the major GlyRs in zebrafish embryos comprise α1 and βb subunits as in mammals. All α subunits form homopentameric GlyRs activated by glycine and inhibited by strychnine and picrotoxin[15]. The β subunits, on the other hand, do not form homomers, while they are incorporated in heteropentameric αβ GlyRs, which is activated by glycine and inhibited by strychnine[5]. Regardless of homomeric α GlyRs or heteromeric αβ GlyRs, glycine binds to the extracellular intersubunit sites, where strychnine also binds as a competitive antagonist and blocks gating of the channel[16]. Picrotoxin binds to the second transmembrane domain of GlyR and clog the channel pore[17]. Interestingly, picrotoxin blocks homomeric α GlyRs at low concentration (~ 10 μM), while ten folds more picrotoxin is necessary to block heteromeric αβ GlyRs in mammals[18]. Collectively, these inhibitors provided striking insights to extend our understanding of GlyR properties. Identification and characterization of new GlyR inhibitors are expected to further improve our knowledge of GlyRs. To search for new chemical compounds that block GlyRs, we screened a chemical library of ~ 1,000 approved drugs and pharmacologically active molecules through their ability to cause touch-evoked bilateral muscle contractions in zebrafish embryos. Strychnine served as a positive control. The screening identified nifedipine and niflumic acids as candidates of GlyR inhibitors. We also found that picrotoxin also affects zebrafish behavior when applied at high concentration. Our electrophysiological recordings using Xenopus oocytes revealed that all of the strychnine, picrotoxin, nifedipine and niflumic acids showed concentration-dependent blockade of glycine-gated currents in both homomeric and heteromeric GlyRs. In both human and zebrafish GlyR cases, the half-maximal inhibitory concentration (IC50) was strychnine < picrotoxin < nifedipine < niflumic acid.

Results

Bath application of nifedipine or niflumic acid affects tactile response of zebrafish

We have previously reported that zebrafish embryos swim when touched at 24 and 48 h postfertilization (hpf), whereas strychnine-treated embryos show obvious shrinkage of the body without swimming due to the loss of GlyR-mediated reciprocal inhibition[13,19]. We assumed that in vivo screening of chemical compounds that cause touch-evoked body shrinkage of zebrafish is a promising way to search for new GlyR inhibitors. To this end, three zebrafish embryos were treated with a drug (10 ~ 100 μM) in a well of 96-well plate at the onset of 24 hpf and then assayed for touch responses at 27 and 48 hpf, when zebrafish embryos show tactile-induced short-distance forward movement and escape swimming, respectively[20]. Among ~ 1,000 drugs that have some known physiological activities, about 79% of the drugs did not affect tactile response, while 10% caused immotile and 10% killed embryos at both stages in our first screening performed in a blind manner. We found 10 drugs that caused touch-evoked body shrinkage or weird uncoordinated response, the latter with contractions of small amplitude and/or compromised rhythmicity (Table 1). We then purchased these drugs, performed second round of screening at several different concentrations and identified three drugs that caused touch-evoked body shrinkage: strychnine, nifedipine and niflumic acid, which are known as specific GlyR inhibitor, voltage-gated calcium channel inhibitor and cyclooxygenase inhibitor, respectively. Successful identification of strychnine in our assay indicates that our screening works well. Nifedipine was previously suggested as a GlyR inhibitor[21]. Although picrotoxin, the other known GlyR inhibitor, was included in our chemical library, we failed to identify it in our screening.
Table 1

List of chemicals and touch-evoked responses of zebrafish embryos.

ChemicalResponse 1st screeningResponse 2nd screeningKnown effectStructureMW
StrychnineBody shrinkageBody shrinkageGlyR antagonistC21H22N2O2334
NifedipineBody shrinkageBody shrinkageCalcium channel blockerC17H18N2O6346
Niflumic acidWeird contractionBody shrinkageAnti-inflammatory agentC13H9F3N2O2282
Mefenamic acidBody shrinkageNormalAnti-inflammatory agentC15H15NO2241
Heptaminol hydrochlorideBody shrinkageNormalMyocardial stimulantC8H20ClNO182
Flavoxate hydrochlorideWeird contractionNormalSmooth muscle relaxantC24H26ClNO4428
DicumarolWeird contractionNormalDepletes vitamin KC19H12O6336
Antimycin AWeird contractionNormalAntibioticsC28H40N2O9549
Papaverine hydrochlorideWeird contractionNormalPhosphodiesterase inhibitorC20H22ClNO4376
Nitrarine dihydrochlorideWeird contractionNormalAntiarrhythmic drugC20H27Cl2N3380

In the first screening, application of either of ten chemicals to zebrafish embryos caused touch-evoked body shrinkage or weird body contraction. The second screening identified thee chemicals as for further analysis.

List of chemicals and touch-evoked responses of zebrafish embryos. In the first screening, application of either of ten chemicals to zebrafish embryos caused touch-evoked body shrinkage or weird body contraction. The second screening identified thee chemicals as for further analysis. We then detailed tactile response of zebrafish embryos at 48 hpf for four drugs: strychnine, picrotoxin, nifedipine and niflumic acid. Upon touch at the tail, control (1% DMSO) zebrafish embryos showed escape swimming by rhythmic side-to-side trunk contractions (Fig. 1a; Supplementary video 1). The shape of the notochord was straight during swimming. Embryos treated with 70 μM strychnine looked normal before touch. However, when touched, they initially exhibited bilateral trunk contractions resulting in the shrinkage of the body and eventually recovered to the normal state (Fig. 1b; Supplementary video 2). The shape of the notochord became zigzag due to the abnormal body compression along the anterior–posterior axis. Bath application of embryos with picrotoxin at 5 mM but not at lower concentrations caused shrinkage of the body following tactile stimulation. Their notochord was corrugated during abnormal touch response (Fig. 1c; Supplementary video 3). Embryos treated with nifedipine at 200 μM displayed bilateral muscle contractions, and as a consequence dorsally bent of the body just like strychnine-treated embryos showed (Fig. 1d; Supplementary video 4). The shape of the notochord was distorted during the response. Likewise, exposure of embryos with 500 μM niflumic acid induced touch-evoked shrinkage of the body and zigzag notochord (Fig. 1e; Supplementary video 5). These abnormal touch responses in the presence of either four drugs were indistinguishable from touch-evoked behaviors of zebrafish GlyR α1 and GlyRβb mutants[13,14]. These results indicate that our in vivo chemical screening using zebrafish embryos was sufficient to identify potential GlyR inhibitors. The order of drug concentration efficient for inducing abnormal touch response was strychnine (70 μM) < nifedipine (200 μM) < niflumic acid (500 μM) < picrotoxin (5 mM).
Figure 1

Bath application of strychnine, picrotoxin, nifedipine or niflumic acid to zebrafish embryos at 48 hpf caused abnormal touch response touch. (a) A superimposed image of 100 Hz movie frames. A control wild-type embryo (1% DMSO) responded to tactile stimulation and showed swimming by side-to-side trunk contractions. (b) Strychnine-treated embryos responded to touch by bilateral muscle contractions that resulted in shortening of the body along anterior–posterior axis. (c) Picrotoxin-treated embryos exhibited similar shrinkage of the body. (d) Nifedipine-treated embryos showed similar abnormal touch response. (e) Niflumic acid-treated embryos also responded to touch by bilateral muscle contractions.

Bath application of strychnine, picrotoxin, nifedipine or niflumic acid to zebrafish embryos at 48 hpf caused abnormal touch response touch. (a) A superimposed image of 100 Hz movie frames. A control wild-type embryo (1% DMSO) responded to tactile stimulation and showed swimming by side-to-side trunk contractions. (b) Strychnine-treated embryos responded to touch by bilateral muscle contractions that resulted in shortening of the body along anterior–posterior axis. (c) Picrotoxin-treated embryos exhibited similar shrinkage of the body. (d) Nifedipine-treated embryos showed similar abnormal touch response. (e) Niflumic acid-treated embryos also responded to touch by bilateral muscle contractions.

Homomeric and heteromeric GlyRs of zebrafish and human origins were formed

To assess the drug sensitivity of GlyRs, we employed electrophysiology using Xenopus oocytes. We first checked glycine-mediated gating of α1 and β subunits of GlyR of zebrafish and human origins, as these subunits were the major GlyR components in vertebrates[9,10,13,14]. We injected cRNAs encoding zebrafish α1 subunit into oocytes, recorded glycine-dependent currents by two-electrode voltage-clamp and detected a concentration-dependent increase of currents for the calculation of half-maximally activated receptor (EC50) and hill coefficients (Fig. 2a,b). Expression of zebrafish α1 subunit with βb subunit also yielded glycine currents, and the cumulative concentration-curve was slightly right-shifted compared with the homomeric zebrafish α1 GlyR case. Similarly, injection of human α1 subunit only and α1 subunit with β subunit in oocytes generated functional homomeric and heteromeric GlyRs, respectively. These zebrafish and human GlyRs were activated by micromolar amounts of glycine and their EC50s were comparable to those in a previous study[22] (Table 2). Injection of zebrafish βb subunit only or human β subunit only into oocytes did not yield currents (data not shown). These data confirm that zebrafish homomeric α1 and heteromeric α1βb GlyRs, as well as human homomeric α1 and heteromeric α1β GlyRs, were properly formed in oocytes.
Figure 2

Heteromeric GlyR decreased glycine sensitivity compared with homomeric GlyR. (a) A trace of two-electrode voltage-clamp recording from oocyte injected with five femtomoles of zGlyRα1 cRNAs exposed to serial application of glycine of increasing amounts. (b) Cumulative concentration–response relationship of glycine-evoked currents. The amplitude of glycine-evoked currents was normalized to the maximally-evoked current as 100% for each oocyte (n = 10). Values here and elsewhere represent mean ± SEM.

Table 2

Summary of glycine-dependent gating of homomeric and heteromeric zGlyR and hGlyR.

EC50 (µM)Hill coefficient
zGlyR α1112 ± 102.7 ± 0.1
zGlyR α1 + zGlyRβb*163 ± 162.5 ± 0.2
hGlyR α1107 ± 7.12.9 ± 0.1
hGlyR α1 + hGlyRβb121 ± 10.23.2 ± 0.2

Values represent the mean ± SEM from 10 oocytes each. Where indicated *p < 0.05 reflects difference between homomeric and heteromeric GlyR.

Heteromeric GlyR decreased glycine sensitivity compared with homomeric GlyR. (a) A trace of two-electrode voltage-clamp recording from oocyte injected with five femtomoles of zGlyRα1 cRNAs exposed to serial application of glycine of increasing amounts. (b) Cumulative concentration–response relationship of glycine-evoked currents. The amplitude of glycine-evoked currents was normalized to the maximally-evoked current as 100% for each oocyte (n = 10). Values here and elsewhere represent mean ± SEM. Summary of glycine-dependent gating of homomeric and heteromeric zGlyR and hGlyR. Values represent the mean ± SEM from 10 oocytes each. Where indicated *p < 0.05 reflects difference between homomeric and heteromeric GlyR.

Niflumic acid blocked both homomeric and heteromeric zebrafish GlyRs by millimolar amounts

Since niflumic acid-treated zebrafish embryos as well as strychnine-, picrotoxin- and nifedipine-treated embryos exhibited abnormal touch response just like zebrafish GlyR mutants showed, niflumic acid likely affect GlyRs as strychnine, picrotoxin and nifedipine do. To address whether these drugs inhibit GlyR, we applied these drugs at different concentrations along with 200 μM glycine to Xenopus oocytes that express zebrafish GlyR α1, recorded currents and calculated IC50 and hill coefficients. In addition to strychnine, picrotoxin and nifedipine, niflumic acid showed concentration-dependent inhibition on homomeric zebrafish α1 GlyRs, suggesting that niflumic acid acts on homomeric α1 GlyRs as an inhibitor (Fig. 3a,b). Similarly, niflumic acid and the other three GlyR inhibitors caused concentration-dependent inhibition of heteromeric zebrafish α1βb GlyRs (Fig. 3c,d). The IC50s and hill coefficients of strychnine, picrotoxin and nifedipine were comparable between against homomeric α1 and against heteromeric α1βb GlyRs, while the IC50 of niflumic acid against homomeric α1 GlyRs were higher than that against heteromeric α1βb GlyRs, indicating that niflumic acid efficiently blocks heteromeric zebrafish GlyRs than homomeric zebrafish GlyRs (Table 3). Although the efficient drug concentrations that induce abnormal touch response in zebrafish embryos was strychnine < nifedipine < niflumic acid < picrotoxin, our electrophysiology suggested the order of IC50s as strychnine < picrotoxin < nifedipine < niflumic acid.
Figure 3

Drug-mediated inhibition of homomeric and heteromeric zebrafish GlyRs. (a) A recording from a zGlyRα1-injected oocyte exposed to 200 µM glycine with increasing amounts of niflumic acid. (b) Cumulative concentration-dependent inhibition of GlyRα1 current by strychnine, picrotoxin, nifedipine and niflumic acid (n = 10 each). (c) A recording from an oocyte, which were injected with zGlyRα1 and zGlyRβb and exposed to 200 µM glycine with increasing amounts of niflumic acid. (d) Cumulative concentration-curves of strychnine, picrotoxin, nifedipine and niflumic acid-mediated inhibition of α1/βb heteromeric zebrafish GlyRs (n = 10 each).

Table 3

Summary of drug-mediated inhibition properties of homomeric and heteromeric zGlyR and hGlyR.

StrychninePicrotoxinNifedipineNiflumic acid
IC50 [nM]Hill coeffIC50 [µM]Hill coeffIC50 [µM]Hill coeffIC50 [µM]Hill coeff
zGlyR α164 ± 130.7 ± 0.26.1 ± 0.31.2 ± 0.1239 ± 380.5 ± 0.1801 ± 910.5 ± 0.1
zGlyR α1 + zGlyRβb68 ± 120.9 ± 0.26.4 ± 0.30.9 ± 0.0162 ± 240.4 ± 0.0**426 ± 440.9 ± 0.1
hGlyR α172 ± 121.0 ± 0.17.2 ± 0.90.9 ± 0.1171 ± 301.1 ± 0.21,074 ± 1451.1 ± 0.2
hGlyR α1 + hGlyRβb92 ± 190.8 ± 0.1***94 ± 19**0.5 ± 0.1130 ± 270.9 ± 0.2930 ± 1111.1 ± 0.1

Values represent the mean ± SEM from 10 oocytes each. Where indicated **p < 0.01, ***p < 0.001 reflect difference between homomeric and heteromeric GlyRs.

Drug-mediated inhibition of homomeric and heteromeric zebrafish GlyRs. (a) A recording from a zGlyRα1-injected oocyte exposed to 200 µM glycine with increasing amounts of niflumic acid. (b) Cumulative concentration-dependent inhibition of GlyRα1 current by strychnine, picrotoxin, nifedipine and niflumic acid (n = 10 each). (c) A recording from an oocyte, which were injected with zGlyRα1 and zGlyRβb and exposed to 200 µM glycine with increasing amounts of niflumic acid. (d) Cumulative concentration-curves of strychnine, picrotoxin, nifedipine and niflumic acid-mediated inhibition of α1/βb heteromeric zebrafish GlyRs (n = 10 each). Summary of drug-mediated inhibition properties of homomeric and heteromeric zGlyR and hGlyR. Values represent the mean ± SEM from 10 oocytes each. Where indicated **p < 0.01, ***p < 0.001 reflect difference between homomeric and heteromeric GlyRs.

Niflumic acid blocked both homomeric and heteromeric human GlyRs at millimolar amounts

We also investigated whether niflumic acid blocks human GlyRs. Exposure of niflumic acid at different concentrations with 200 μM glycine to Xenopus oocytes that express human GlyR α1 revealed that niflumic acid blocked GlyR in a concentration-dependent manner (Fig. 4a,b). Our electrophysiology confirmed that strychnine, picrotoxin and nifedipine also blocked homomeric human α1 GlyRs. Likewise, niflumic acid and the other three GlyR inhibitors showed concentration-dependent inhibition on heteromeric human α1β GlyRs (Fig. 4c,d). The IC50s and hill coefficients of strychnine, nifedipine and niflumic acid were comparable between against homomeric α1 and against heteromeric α1β GlyRs. As reported previously, the IC50 of picrotoxin against heteromeric human α1β GlyRs were significantly higher than that against homomeric human α1 GlyRs[18]. The order of IC50s was strychnine < picrotoxin < nifedipine < niflumic acid. Taken together, these results indicate that niflumic acid is an inhibitor of GlyR.
Figure 4

Drug-mediated inhibition of homomeric and heteromeric human GlyRs. (a) A recording from a hGlyRα1-injected oocyte exposed to 200 µM glycine with increasing amounts of niflumic acid. (b) Cumulative concentration-dependent inhibition of GlyRα1 current by strychnine, picrotoxin, nifedipine and niflumic acid (n = 10 each). (c) A recording from an oocyte, which were injected with hGlyRα1 and hGlyRβ and exposed to 200 µM glycine and increasing amounts of niflumic acid. (d) Cumulative concentration-curves of strychnine, picrotoxin, nifedipine and niflumic acid-mediated inhibition of α1/β heteromeric human GlyRs (n = 10 each).

Drug-mediated inhibition of homomeric and heteromeric human GlyRs. (a) A recording from a hGlyRα1-injected oocyte exposed to 200 µM glycine with increasing amounts of niflumic acid. (b) Cumulative concentration-dependent inhibition of GlyRα1 current by strychnine, picrotoxin, nifedipine and niflumic acid (n = 10 each). (c) A recording from an oocyte, which were injected with hGlyRα1 and hGlyRβ and exposed to 200 µM glycine and increasing amounts of niflumic acid. (d) Cumulative concentration-curves of strychnine, picrotoxin, nifedipine and niflumic acid-mediated inhibition of α1/β heteromeric human GlyRs (n = 10 each).

Discussion

In this study, we employed chemical screening using zebrafish embryos to search for new GlyR inhibitors. Among ~ 1,000 approved drugs and pharmacologically active molecules, niflumic acid was identified as a candidate. We then performed Xenopus oocyte physiology and calculated IC50s and hill coefficients of niflumic acid against zebrafish and human GlyRs. Interestingly, the sufficient drug concentrations that induce abnormal touch response in zebrafish embryos were strychnine < nifedipine < niflumic acid < picrotoxin, the values of IC50 of GlyR was strychnine < picrotoxin < nifedipine < niflumic acid.

In vivo chemical screening to identify new GlyR inhibitors

Although many zebrafish-based chemical screenings use transgenic or mutant zebrafish and thus need to select transgene-positive or mutation-carrying embryos/larvae, our screening uses wild-type zebrafish embryos at 48 hpf without any selection, enabling easy sample collection for the screening. In our chemical library, drugs were initially solved in DMSO and eventually diluted to 1/100 in each well of a 96-well plate for treatment. Thus, zebrafish embryos are exposed to drugs in the presence of 1% DMSO. This DMSO concentration facilitates the penetration of drugs into zebrafish body and is harmless. With these advantages, our in vivo drug screening tested ~ 50 drugs in a week and identified strychnine, nifedipine and niflumic acid as potential GlyR inhibitors. Interestingly, we failed to identify picrotoxin in this screening. But this was reasonable because 5 mM concentration of picrotoxin was necessary for inducing abnormal touch response. Since we succeeded in identifying three GlyR inhibitors from ~ 1,000 drugs, we will be able to find many novel ones if we expand the screening scale. While inhibition of GlyR impairs glycinergic transmission that results in the body shrinkage in zebrafish embryos, inhibition of glial glycine transporter 1 (GlyT1) causes synaptic accumulation of glycine and thus potentiates inhibitory glycinergic transmission, leading to reduction of touch response[23]. Although sarcosine, which is GlyT1 inhibitor, was not included in our chemical library, if it was, body contractions with small amplitude could be seen.

Niflumic acid as a GlyR inhibitor

An anti-inflammation drug niflumic acid blocks cyclooxygenase-2 and is clinically used to reduce joint and muscular pain in rheumatoid[24]. It is also known as a blocker of calcium-activated chloride channels[25], voltage-gated chloride channels[26], NMDA receptors[27] and GABAA receptors[28]. Here we found that niflumic acid blocks both homomeric and heteromeric human GlyRs. Recent studies have investigated that niflumic acid affects human GlyRs expressed in CHO cells with higher blocking potency in homomeric α2 and α3 GlyRs than in homomeric α1 GlyRs[29]. Our electrophysiology results assayed in Xenopus oocytes were consistent with their human GlyR results. Since we could also reveal niflumic acid-sensitivity of zebrafish GlyRs and niflumic acid-induced motor deficits in zebrafish embryos, niflumic acid-mediated GlyR inhibition is assumed to be conserved among vertebrates.

Effective drug concentration for blocking zebrafish GlyRs in Xenopus oocytes and zebrafish embryos

Our electrophysiology in Xenopus oocytes and touch-evoked response in zebrafish embryos revealed the effective concentration of drugs in vitro and in vivo, respectively. In the case of strychnine and picrotoxin, the effective concentrations for GlyR inhibition in zebrafish embryos (strychnine: 70 μM; picrotoxin: 5 mM) were 1,000 folds higher than the IC50 values of GlyRs expressed in Xenopus oocytes (strychnine: 70 nM; picrotoxin: 6 μM). This 1,000 fold difference is likely due to the low penetration of drugs through the skin. On the other hand for nifedipine and niflumic acid, the effective concentrations to induce abnormal touch response in zebrafish embryos (nifedipine: 200 μM; niflumic acid: 500 μM) were comparable to IC50s of GlyRs in oocyte physiology (nifedipine: 200 μM; niflumic acid: 400 μM). Since both of these drugs are insoluble to water and thus hydrophobic, they can be highly permeable to the skin.

Material and methods

Reagents

All chemicals and reagents except for library drugs for chemical screening were purchased from Wako Pure Chemical Industries and Thermo Fisher Scientific and used according to manufactures guidelines.

Animal care and use

Zebrafish (Danio rerio) were reared and maintained at 28.5 °C under a 14 h light and 10 h dark photoperiod and fed twice a day in accordance with the Animal Care and Use Committee at Aoyama Gakuin University. Larvae were staged according to the established guidelines[30], and are given as hours post-fertilization. At the ages we examined, sex determination has not yet occurred in zebrafish embryos.

Drug screening

Two chemical libraries from Kyoto University and Nagoya University, composed of total ~ 1,000 bioactive compounds, were used in this study. The 2 µl of chemical compounds (1 ~ 10 mM) dissolved in DMSO were diluted to 200 µl with E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4) and transferred to 96-well plate. Three zebrafish embryos (24 hpf) were transferred into each well of the plate and incubated in a 28.5 °C incubator. At 27 hpf, three embryos with a small amount of drug solution were transferred to a 90-mm dish containing 15 ml of E3 medium and subjected to touch response using forceps under a dissection microscope Leica MZ16. After this assay, embryos with a small amount of E3 solution were transferred back to the drug solution in 96-well plate and incubated in the 28.5 °C incubator. At 48 hpf, embryos were transferred to a 90-mm dish containing 15 ml of E3 medium again and subjected to the touch response. The positive control for this assay was 70 µM strychnine, and the negative control was 1% DMSO.

Video recording of zebrafish touch response

Tactile-evoked zebrafish movements in the presence of control 1% DMSO or drug were video recorded at 48 hpf using a dissection microscope. Touch responses elicited by tactile stimulation delivered to the tail with forceps were captured with a high-speed CCD camera at 200 frames per second (HAS-220, Ditect) as described previously[31]. Embryos were exposed to 70 µM strychnine, 5 mM picrotoxin, 200 µM nifedipine, 500 µM niflumic acid for 30 min before assay.

Electrophysiology

Full-length cDNAs encoding zebrafish GlyR α1 and βb and human GlyR α1 and β subunits were used in this study. Capped cRNAs for expression in Xenopus laevis oocytes were synthesized from linearized templates using SP6 mMessage mMachine SP6 transcription kit (Thermo Fisher Scientific) as described previously[32]. Oocytes were injected with five femtomoles of cRNA using a Nanoject II (Drummond Scientific). Oocytes were moved to 48-well plates in Barth’s solution (88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.33 mM Ca (NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 mM HEPES at pH 7.5 with NaOH, supplemented with 50 µg/ml gentamicin and 100 units/ml penicillin/streptomycin) and incubated at 18 °C for 24–48 h prior to recording. Oocyte recording solution (90 mM NaCl, 1 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES at pH 7.5 with NaOH) and drug solutions of seven different concentrations were flew into the oocyte chamber using a BPS-8 solution switcher (ALA Scientific). Borosilicate electrodes had resistances of ~ 2.0 MΩ when filed with 3 M KCl. Two-electrode voltage clamp recordings were made from oocytes held at − 70 mV using pClamp 10.2 to control a GeneClamp 500B amplifier via a Digidata 1440A digitizer (Molecular Devices) as described previously[33]. Signals were low-pass filtered at 10 Hz, and sampled at 100 Hz. Recordings were analyzed using Clampfit 10.7 (Axon Instruments) and SigmaPlot 11.0 (Systat Software, Inc.). EC50s, IC50s and Hill coefficients were calculated sigmoid standard curve as below.x: glycine concentration (EC50) or antagonist concentration (IC50). y: normalized current. Statistical significance was assessed using the pair-wise analysis of variance.

Ethics statement

All animal experiments described in this manuscript and guidelines for use of zebrafish have been approved by Animal Care and Use Committee in Aoyama Gakuin University. Supplementary file1 Supplementary file2 Supplementary file3 Supplementary file4 Supplementary file5 Supplementary file6
  32 in total

Review 1.  Structure and functions of inhibitory and excitatory glycine receptors.

Authors:  H Betz; J Kuhse; V Schmieden; B Laube; J Kirsch; R J Harvey
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

2.  Niflumic acid in the management of rheumatoid and osteoarthritis.

Authors:  G H Tilve; J K Lengade; A V Bavadekar; K G Nair
Journal:  J Postgrad Med       Date:  1976-07       Impact factor: 1.476

3.  Alternative splicing generates two isoforms of the alpha 2 subunit of the inhibitory glycine receptor.

Authors:  J Kuhse; A Kuryatov; Y Maulet; M L Malosio; V Schmieden; H Betz
Journal:  FEBS Lett       Date:  1991-05-20       Impact factor: 4.124

4.  Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB).

Authors:  Mark I Rees; Trevor M Lewis; John B J Kwok; Geert R Mortier; Paul Govaert; Russell G Snell; Peter R Schofield; Michael J Owen
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

5.  Zebrafish hox clusters and vertebrate genome evolution.

Authors:  A Amores; A Force; Y L Yan; L Joly; C Amemiya; A Fritz; R K Ho; J Langeland; V Prince; Y L Wang; M Westerfield; M Ekker; J H Postlethwait
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

6.  Chloride transport blockers prevent N-methyl-D-aspartate receptor-channel complex activation.

Authors:  J Lerma; R Martín del Río
Journal:  Mol Pharmacol       Date:  1992-02       Impact factor: 4.436

7.  The atypical M2 segment of the beta subunit confers picrotoxinin resistance to inhibitory glycine receptor channels.

Authors:  I Pribilla; T Takagi; D Langosch; J Bormann; H Betz
Journal:  EMBO J       Date:  1992-12       Impact factor: 11.598

8.  Alpha subunit variants of the human glycine receptor: primary structures, functional expression and chromosomal localization of the corresponding genes.

Authors:  G Grenningloh; V Schmieden; P R Schofield; P H Seeburg; T Siddique; T K Mohandas; C M Becker; H Betz
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598

9.  Voltage-Dependent Inhibition of Glycine Receptor Channels by Niflumic Acid.

Authors:  Galyna Maleeva; Franck Peiretti; Boris S Zhorov; Piotr Bregestovski
Journal:  Front Mol Neurosci       Date:  2017-05-16       Impact factor: 5.639

10.  A proposed structural basis for picrotoxinin and picrotin binding in the glycine receptor pore.

Authors:  Zhe Yang; Brett A Cromer; Robert J Harvey; Michael W Parker; Joseph W Lynch
Journal:  J Neurochem       Date:  2007-08-20       Impact factor: 5.372

View more
  3 in total

Review 1.  Effects of glycine on metabolic syndrome components: a review.

Authors:  M Imenshahidi; H Hossenzadeh
Journal:  J Endocrinol Invest       Date:  2022-01-11       Impact factor: 4.256

2.  Characterization of zebrafish GABAA receptor subunits.

Authors:  Kenichiro Sadamitsu; Leona Shigemitsu; Marina Suzuki; Daishi Ito; Makoto Kashima; Hiromi Hirata
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

3.  Genome-Wide Selective Signature Analysis Revealed Insecticide Resistance Mechanisms in Cydia pomonella.

Authors:  Wen-Ting Dai; Jin Li; Li-Ping Ban
Journal:  Insects       Date:  2021-12-21       Impact factor: 2.769

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.